Tasedan

Quick links to important sections

Tasedan

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tasedan

What is Tasedan? Foundational Identity and Purpose

Property Description
Active ingredient Estazolam
Form Tablet (Oral Route)
Pharmacological class Benzodiazepine, CNS Depressant
General purpose Promotes a restful and tranquil state
Origin Synthetic organic compound

Tasedan: A Triazolobenzodiazepine Chemical Identity

Tasedan is the trade name for the active substance Estazolam, which is a prescription-only medication and a synthetic organic compound categorized as a triazolobenzodiazepine derivative. This chemical structure places it within the larger benzodiazepine group of drugs, fundamentally classified as a Central Nervous System (CNS) Depressant. Estazolam is designated an oral hypnotic agent, a classification clinically recognized for its action in managing conditions related to sleep difficulties. The compound's function is to modulate brain activity, positioning it specifically as an intermediate-acting agent for adult patients.


Composition and Physical Form of Estazolam

The core composition of Tasedan involves the single active ingredient, Estazolam, delivered as an orally available formulation in the form of a tablet. Estazolam is combined with standard pharmaceutical excipients to create this stable, measurable oral dosage form. This deliberate composition ensures that the patient receives only the targeted triazolobenzodiazepine compound via the oral route of administration. The tablet form differentiates it from other formulations in the benzodiazepine category that may be available as solutions or injectables.


What General Benefit Does Tasedan Provide?

The general purpose of Tasedan is to help the body and mind achieve a state of restfulness due to its sedative and hypnotic properties. It functions by enhancing the effects of the brain’s primary inhibitory neurotransmitter, Gamma-Aminobutyric Acid (GABA), which increases neuronal inhibition and reduces the overall excitability of nerve cells. This enhancement of the natural calming processes provides the foundational action for promoting tranquility and general relaxation.

Regulatory References

  1. FDA Estazolam Label
  2. Estazolam DailyMed

What side effects are possible with Tasedan?

Possible Side Effects and Safety Information

The safety profile of Estazolam (Tasedan), a central nervous system depressant, is defined by adverse reactions classified by government regulatory documents. The most commonly reported side effects involve the Nervous System and are consistent with its hypnotic class, including somnolence, dizziness, headache, and fatigue. Less common events reported in regulatory data include abnormal thinking, confusion, and memory impairment.


Serious Adverse Reactions and Behavioral Safety

The official labeling documents certain serious and clinically significant adverse reactions. These include the potential for complex sleep behaviors (such as sleep-driving or making calls while not fully awake with subsequent amnesia) and paradoxical reactions like agitation, aggression, or hallucinations. There is also a documented risk for the worsening of depression and suicidal ideation. Co-administration with opioids or other CNS depressants significantly increases the risk of profound sedation and respiratory depression.


Duration and Population-Specific Safety

Estazolam is classified as a Schedule IV controlled substance due to the potential for abuse and dependence, with the risk increasing with the duration of use. Abrupt or rapid discontinuation after chronic use may lead to withdrawal symptoms or the temporary recurrence of insomnia symptoms with increased severity (rebound insomnia).

Older adults are noted in regulatory information as being more susceptible to the central effects, such as dizziness and unsteadiness, which can increase the risk of falls. The medicine is contraindicated in pregnancy and its use should be approached with caution in patients with hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

Tasedan is a trade name for the substance estazolam, which belongs to the benzodiazepine class. An overdose, which may occur when the drug is taken in excessive amounts or in combination with other central nervous system (CNS) depressants, constitutes a medical emergency.

Clinical Manifestations of Overdose

The primary effect of an isolated overdose is marked CNS depression. Signs and symptoms generally range from mild to severe and may include:

  • Drowsiness or Extreme Sleepiness
  • Confusion and Loss of Coordination (Ataxia)
  • Slurred Speech
  • Slowed or Shallow Breathing (Respiratory Depression)
  • Coma (Loss of Consciousness)

Severe outcomes, including profound respiratory depression, coma, and death, are significantly more likely when Tasedan (estazolam) is combined with substances such as alcohol, opioids, or other sedative-hypnotics.

Required Emergency Actions

Immediate medical attention is required for any suspected overdose. Do not wait for symptoms to worsen. If a person is unresponsive, has severely slowed or stopped breathing, is difficult to wake, or has blue/pale lips or fingertips, call for emergency medical services right away. While waiting for help, ensure the person is on their side to prevent choking if vomiting occurs. Treatment focuses on supportive care to maintain breathing and heart function in a monitored clinical setting. (198 words)

Therapeutic Uses of Tasedan

What Tasedan Treats: Main Uses and Benefits

The medication is used in areas where short-term symptom management is appropriate, particularly for sleep-related issues. The medication is indicated for the short-term management of insomnia.


Managing Short-Term Difficulty Falling Asleep and Staying Asleep

The medication is applied across therapeutic domains where additional symptomatic support is needed for sleep disturbances. Specifically, it is used for managing symptom clusters that may become intense or disruptive, such as difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. It is used in clinical settings that involve acute or unstable symptom patterns, relevant when supportive symptom management is appropriate. This provides support that helps ease the overall symptom burden and contributes to improved comfort during symptomatic periods.

“This medication may assist with maintaining functional stability by supporting a more restful night's sleep during difficult episodes.”

Supportive Relief for Anxiety-Related Symptoms

The medication is generally considered relevant for symptomatic management in conditions characterized by periods of heightened symptoms, which may include anxiety and emotional tension, especially when they contribute to sleep disruption. It assists in addressing symptom clusters that may appear suddenly or fluctuate, offering symptomatic relief that supports the patient during difficult episodes by easing distress and helping to maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Relief for Sleep Onset and Maintenance Insomnia

Regulatory References

  1. DailyMed official drug label

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Tasedan — Official Regulatory Information

Regulatory documents define population eligibility for Tasedan (Estazolam) by establishing absolute prohibitions, conditional use requirements, and age-related restrictions. The medicine is primarily established for use in adult patients requiring short-term insomnia management.


Contraindicated Populations

Category Official Regulatory Statement
Absolute Contraindication Patients with known hypersensitivity to estazolam or other benzodiazepines.
Reproductive Status Women who are pregnant or who may become pregnant (Pregnancy Category X).
Concomitant Therapy Patients receiving strong CYP3A4 inhibitors, specifically ketoconazole or itraconazole.

Restricted and Conditional Use

Population/Condition Regulatory Restriction Summary
Age Restriction Safety and effectiveness have not been established in pediatric patients (under 18).
Older Adults (65+) Use requires special caution due to increased sensitivity to adverse effects.
Organ Impairment Use with caution in patients with hepatic impairment (liver disease) or renal impairment (kidney disease).
Comorbidity History Use with caution in patients with a history of alcohol/drug abuse or depressive disorders.
Lactation Use is generally not recommended for nursing women (breastfeeding).

Connection to the Overall Eligibility Profile

Official regulatory information restricts the use of Tasedan to the adult population by establishing clear absolute exclusions based on the risk of fetal harm and drug-drug interactions. The profile dictates that use is not established for children, and requires explicit special consideration and caution for older adults and individuals with pre-existing conditions affecting organ function or mental health history.

What should I know about interactions with other medicines?

Tasedan Interactions with other medicines and products

Official regulatory documents structure the interaction profile of Tasedan by identifying specific classes of agents that significantly modify its exposure or potentiate its central effects. The primary documented constraints relate to pharmacokinetic (PK) interactions involving the Cytochrome P450 3A (CYP3A) enzyme system. Tasedan's metabolism is dependent on CYP3A, leading to specific constraints with strong inhibitors of this enzyme.

Interaction Scope
Medicinal product categories with documented interactions: Opioid analgesics, strong CYP3A inhibitors, other Central Nervous System (CNS) depressants.
Specific interacting medicines (if explicitly listed): Itraconazole and Ketoconazole are specifically contraindicated; Ritonavir is also noted as having the potential for significant interaction.
Mechanistic basis of interactions (only if stated in label): Inhibition of CYP3A enzyme, which decreases the metabolism of Tasedan and increases its plasma concentration. Additive CNS depressant effects.
Interaction-related restrictions: Co-administration with strong CYP3A inhibitors (e.g., itraconazole, ketoconazole) is officially contraindicated. The use of Tasedan with opioids must be avoided unless alternatives are inadequate, due to the risk of profound sedation and respiratory depression.

Official interaction statements highlight the necessity to use Tasedan cautiously with drugs that are less potent CYP3A inhibitors and with other CNS depressants, which include certain antidepressants and sedatives. Concomitant use with alcohol also results in additive CNS depressant effects, and is officially advised against. While no explicit timing-based rules are stated for most co-administered drugs, the regulatory information emphasizes close monitoring for increased sedation and respiratory issues when Tasedan is used alongside other CNS depressants.

Mechanism of Action

Positive Allosteric Modulation of GABA A Receptors

Tasedan (Estazolam) acts as a Positive Allosteric Modulator (PAM) by binding to a specific site on the GABA A Receptor Complex in the Central Nervous System (CNS). This mechanism does not activate the receptor directly but increases the effect of the natural inhibitory neurotransmitter GABA on the primary inhibitory signaling cascade in the brain.

Cl^- Flux and Neuronal Hyperpolarization

The potentiated GABA action increases the frequency of opening for the receptor's chloride ion ( Cl^-) channel, leading to a substantial influx of negative ions. This cellular event results in neuronal hyperpolarization, which reduces the cell's ability to transmit electrical impulses, thereby lowering the overall excitability of CNS circuits.

Cascade to Systemic CNS Depression

The widespread hyperpolarization of neurons initiates a molecular cascade that translates into generalized CNS depression, the observable physiological effect of the drug. This dampening of neural activity is the core mechanism that lowers brain arousal and motor tone, aligning with the requirements for pathway-level modulation.

Dosage and Administration Information

The usage of Tasedan (Estazolam) is strictly defined by administration patterns. The medication is an oral formulation supplied as a tablet in strengths of 1 mg and 2 mg. Administration is strictly via the oral route.

The standard adult regimen involves taking the medication once daily (qHS) immediately prior to bedtime. The typical starting dose is 1 mg, which may be adjusted up to a maximum recommended dose of 2 mg once per day. Dosing requires high contextual adherence: the tablet should not be taken with or right after a heavy meal to avoid delays in its onset, and administration is contingent on the patient being able to commit to a full night's sleep of 7 to 8 hours.

For specific patient populations, usage is modified. For older adults or debilitated patients, a lower initial dose of 0.5 mg at bedtime is specified. The medication is explicitly approved for short-term use only, and following any period of sustained administration, a gradual dose tapering schedule is required upon discontinuation to manage procedural changes. If a dose is missed, the instructions state that a patient should not take a double dose, but should resume the planned schedule instead.

Recent Clinical Evidence

Research evidence / Overview of studies for Tasedan

Evidence for Use in Short-Term Insomnia Management

The research for Tasedan primarily consists of Randomized Controlled Trials (RCTs), a study design used for investigating medicines. These short-term RCTs were applied in studies examining patient-reported experiences and monitoring physiological strain or stress in adult outpatients with insomnia. The trials typically included comparison groups, such as those receiving an inactive substance (placebo) or those receiving other compounds under investigation. Research examined measures related to sleep initiation (how long it takes to fall asleep) and sleep maintenance (how often a person wakes up and the total duration of sleep).

Studies report patterns related to how symptoms changed in the observed populations across short treatment periods, often lasting from seven to fourteen nights. Findings describe patterns observed in the studies related to the time taken to fall asleep and in metrics related to staying asleep, such as the total time spent sleeping. Research highlights changes measured during the study period, including metrics for the number of nocturnal awakenings.


Long-Term Research and Durability of Findings

While the core research focused on short-term data, studies have also explored observed changes over defined time intervals that extend beyond two weeks. Some clinical trials have monitored patients for up to six to twelve weeks to evaluate patterns over a longer, though still intermediate, duration. These intermediate-term studies monitored changes in sleep metrics over a more extended observation period.

However, long-term effects are not fully established. There is limited information for long-term outcomes and functional stability when use extends beyond a few months. Data are still emerging for observation periods lasting longer than 12 weeks. Therefore, the evidence helps contextualize how patients reported their experience during acute and intermediate-term use, but there is limited information for long-term outcomes.


Unanswered Questions and Research Gaps

Research explored Tasedan in specific populations, particularly the older adult population. Studies observed patterns related to symptom intensity or variability in older individuals. Research data for certain groups, such as children and adolescents, remain insufficient, meaning that the findings apply only to the populations studied.

A primary research limitation is that long-term effects are not fully established beyond the intermediate follow-up durations seen in the main trials. Furthermore, sample sizes were small in some of the older studies, and evidence quality varies across studies. Comparative evidence is lacking, and subgroup findings are uncertain. Research provides context but not individual predictions, and the findings describe group patterns, not personal outcomes, indicating that individual responses may vary significantly.

Key Studies & References

  1. DailyMed - ESTAZOLAM tablet (Official FDA Labeling)

Frequently Asked Questions (FAQ)

Common questions about Tasedan (FAQ)


Q: Is Tasedan a type of antidepressant or something else?

A: Tasedan (Estazolam) is classified as a triazolobenzodiazepine, which is a type of Central Nervous System (CNS) Depressant. According to official product information, it is designated as a prescription-only hypnotic agent (sleep aid), and is not classified as an antidepressant.


Q: Is Tasedan considered a mood stabilizer?

A: No, Tasedan is not classified as a mood stabilizer. Regulatory documents classify Tasedan as a benzodiazepine and a hypnotic agent, indicated for the short-term management of insomnia.


Q: What are the main benefits of taking Tasedan?

A: Tasedan is approved for the short-term management of insomnia. Regulatory documents indicate that the drug is approved to manage symptoms of insomnia, which may include difficulty falling asleep, nocturnal awakenings, and early morning awakenings.


Q: Does Tasedan help with sleep problems too?

A: Tasedan is a hypnotic agent specifically indicated for the short-term management of insomnia, a type of sleep difficulty.


Q: Is Tasedan fast-acting or does it take time to work?

A: Tasedan is an intermediate-acting drug. Regulatory instructions specify that it is intended to be taken immediately prior to bedtime to initiate its effect.


Q: How long until I might feel the full effect of Tasedan?

A: Peak concentrations of the drug in the blood are generally reached within two hours after dosing in healthy subjects. This is the time frame where the peak sedative effect has been observed in studies.


Q: Can you take Tasedan on an empty stomach?

A: The regulatory instruction advises caution to avoid taking the tablet with or right after a heavy meal, as this may delay the onset of the drug’s effects. The regulatory information focuses only on the caution to avoid taking it with a heavy meal.


Q: Are there any side effects that are considered very serious for Tasedan?

A: Yes, serious adverse reactions reported in official warnings include complex sleep behaviors (like sleep-driving with amnesia) and profound sedation/respiratory depression, especially when taken with opioids. The label also contains a warning regarding the potential for worsening depression and the emergence of suicidal ideation.


Q: Is feeling groggy normal when first starting Tasedan?

A: Drowsiness (somnolence) and fatigue are among the most commonly observed side effects reported in official documentation. These effects are consistent with the drug’s action as a Central Nervous System depressant.


Q: Can I drink coffee or caffeine while taking Tasedan?

A: Official information does not specifically mention coffee or caffeine. However, the regulatory warnings focus on the risk of additive CNS depressant effects from substances like alcohol and certain medicines.


Q: Are there any supplements that should not be taken with Tasedan?

A: Tasedan is metabolized by the CYP3A enzyme, so supplements that strongly inhibit this enzyme may increase the drug's levels in the body. The use of strong CYP3A inhibitors may result in increased exposure to Tasedan, and this requires careful review by a healthcare professional.


Q: Is it safe to drive after taking Tasedan?

A: The label warns against driving or operating heavy machinery until an individual is certain the drug does not cause impairment. This warning is due to common side effects like drowsiness, dizziness, and impaired coordination.


Q: Is Tasedan prescribed to children or teens?

A: The safety and effectiveness of the medication have not been established in patients under 18 years of age.


Q: Is there any risk of dependence with Tasedan?

A: Yes. Tasedan is a Schedule IV controlled substance due to its potential for abuse and dependence. The risk of abuse and dependence is generally understood to increase with the duration of use and dose size.


Q: How does stopping Tasedan affect a person?

A: To minimize the risk of withdrawal symptoms or rebound insomnia, regulatory instructions require a gradual dose tapering schedule upon discontinuation after a period of sustained use.


Q: Is Tasedan a newer drug, or has it been around for a while?

A: Tasedan’s active ingredient, Estazolam, is a triazolobenzodiazepine derivative. The chemical structure is part of a class of compounds that have been recognized in pharmaceutical history since the 1970s.


Q: Where can I find reliable research papers on Tasedan?

A: Relevant research on the active ingredient, Estazolam, can be accessed by searching official scientific literature databases, such as the NIH/PubMed, or by reviewing the FDA’s official drug approval documents.


Q: Are there any studies showing Tasedan's long-term effects?

A: The primary clinical studies supporting its use were short-term (e.g., 7 to 14 nights). Official documentation states that the long-term effects for use extending beyond a few months are not fully established.


Q: How long does Tasedan stay in your system?

A: The mean elimination half-life of Estazolam in healthy young adults is approximately 19 hours. This time frame can vary widely in different individuals.


Q: Why do some people say Tasedan made them feel restless?

A: Official warnings note that Tasedan can cause abnormal thinking and behavioral changes. These include paradoxical reactions such as agitation and aggression, and restlessness is also listed as a post-marketing adverse event.


Q: Can I take Tasedan if I have a heart condition?

A: Heart conditions are not listed as an absolute contraindication. However, adverse reaction reports include cardiovascular events such as palpitations and arrhythmias. Individuals with heart conditions should discuss all risks and benefits with a healthcare professional.


Q: Is it possible to have an allergic reaction to Tasedan?

A: Yes, Tasedan is contraindicated for anyone with a known hypersensitivity to the drug. Rare but serious allergic reactions have been reported, including angioedema (swelling of the face, tongue, or throat).


Q: Are there any dietary restrictions when using Tasedan?

A: Official instructions advise caution to avoid taking the dose with or right after a heavy meal, as this may delay the onset of the drug's effects. The label also advises against co-administration with alcohol.


Q: Does Tasedan make you feel tired during the day?

A: Official reports indicate that common side effects, such as drowsiness (somnolence) and fatigue, have the potential to extend into the next day. These effects are consistent with the drug’s mechanism as a Central Nervous System depressant.


Q: Is Tasedan known to interact with herbal remedies like St. John's Wort?

A: Yes, St. John's Wort is noted in the regulatory information as an agent that may interact with Estazolam. This is generally related to the drug's metabolism.


Q: What are the signs that Tasedan is starting to work?

A: As a hypnotic agent, the expected indication that the drug is taking effect is the onset of its sedative properties, which promotes sleep.


Q: Is Tasedan used for pain management in any cases?

A: Tasedan is indicated solely for the short-term treatment of insomnia. However, the label contains a Boxed Warning regarding the significant risk when used concurrently with opioid pain medicines.


Q: Is it normal to have vivid dreams when taking Tasedan?

A: The regulatory documents list 'Abnormal dreams' as a reported adverse reaction associated with Tasedan use, which may cover the experience of vivid dreams.


Q: What should be avoided when taking Tasedan?

A: Official warnings advise against the co-administration of Tasedan with alcohol and other Central Nervous System (CNS) depressants, including opioids, due to the risk of profound sedation and respiratory depression.


Q: Can Tasedan affect my mood in unexpected ways?

A: Yes. The regulatory label warns that Tasedan can cause abnormal thinking and behavioral changes. These changes can include paradoxical reactions like agitation, as well as the worsening of depression and potential for suicidal thoughts.


Q: What is the standard duration of Tasedan treatment?

A: Tasedan is officially approved only for the short-term management of insomnia. The clinical trials supporting its use were primarily short-term.


Q: Does Tasedan affect my blood pressure?

A: While not a common side effect, adverse reaction reports include cardiovascular events such as flushing, palpitations, and in rare cases, syncope (fainting) and arrhythmia.


Q: Is there a generic version of Tasedan available?

A: The active ingredient in Tasedan is Estazolam. This ingredient is available in generic formulations.


Q: What should I do if I experience a rare side effect from Tasedan?

A: Official guidance states that severe or life-threatening symptoms, such as an allergic reaction or breathing difficulties, require immediate medical attention. For less severe symptoms, a healthcare professional should be contacted.

How should Tasedan be stored and disposed of?

How to Store and Dispose of Tasedan (Estazolam)

Storage and disposal procedures for Tasedan must align strictly with official regulatory requirements to ensure product stability and safety, particularly due to its classification as a controlled substance.

Official Storage Conditions

Tasedan must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F). The product must be protected from freezing, excess heat, moisture (do not store in the bathroom), and direct light. The tablets must be kept in the original container, which should be tightly closed.

Child Safety and Disposal

To prevent accidental exposure or misuse, the medication must be kept out of the reach of children and stored in a safe, secure location. Disposal of unused or expired Tasedan should prioritize professional programs, such as drug take-back locations, following the advice of a healthcare professional. Tasedan should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Tasedan found in:

A-Z Index: